{"id":4728,"date":"2021-10-13T10:40:00","date_gmt":"2021-10-13T10:40:00","guid":{"rendered":"https:\/\/nanexa.com\/mfn_news\/nanexa-tecknar-ytterligare-utvarderingsavtal\/"},"modified":"2021-10-13T10:40:00","modified_gmt":"2021-10-13T10:40:00","slug":"nanexa-tecknar-ytterligare-utvarderingsavtal","status":"publish","type":"mfn_news","link":"https:\/\/nanexa.com\/sv\/mfn_news\/nanexa-tecknar-ytterligare-utvarderingsavtal\/","title":{"rendered":"Nanexa tecknar ytterligare utv\u00e4rderingsavtal"},"content":{"rendered":"<div class=\"mfn-preamble\">\n<p><strong>Nanexa AB meddelar idag att bolaget har tecknat ytterligare ett s\u00e5 kallat Material Transfer and Feasibility Study Agreement med en av bolagets befintliga kunder, f\u00f6r utv\u00e4rdering av PharmaShell\u00ae-teknologin med en specifik biologisk l\u00e4kemedelssubstans.<\/strong><\/p>\n<\/div>\n<div class=\"mfn-body\">\n<p>Nanexa har tidigare samarbetat med detta stora l\u00e4kemedelsbolag kring PharmaShell-teknologin och dess m\u00f6jligheter i kombination med olika l\u00e4kemedelssubstanser. Detta \u00e4r ytterligare ett steg i det samarbetet.<\/p>\n<p>\u201dDet \u00e4r mycket sp\u00e4nnande att forts\u00e4tta samarbetet som med detta avtal g\u00e5r in i en ny fas. Vi ser fram emot att p\u00e5b\u00f6rja det praktiska arbetet inom kort och att denna utv\u00e4rdering kan generera resultat som kan ligga till grund f\u00f6r ett djupare och l\u00e5ngsiktigt produktutvecklingsavtal\u201d, s\u00e4ger David Westberg, vd f\u00f6r Nanexa.<\/p>\n<p>Avtalet reglerar bland annat detaljer om vad som ska unders\u00f6kas och klarg\u00f6rande om patentr\u00e4ttigheter samt en fastlagd mindre ers\u00e4ttning som tillfaller Nanexa f\u00f6r denna utv\u00e4rdering.<br \/>\u00a0<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-contacts\">\n<p><strong class=\"mfn-heading-1\">F\u00f6r mer information kontakta:<\/strong><\/p>\n<hr \/>\n<p>David Westberg \u2013 VD, Nanexa AB (publ)\u00a0<br \/>Telefon: 0709-42 83 03<br \/>E-post:\u00a0<a href=\"mailto:david.westberg@nanexa.se\" target=\"_blank\" rel=\"nofollow noopener\">david.westberg@nanexa.se<\/a><br \/><a href=\"http:\/\/www.nanexa.com\" target=\"_blank\" rel=\"nofollow noopener\">www.nanexa.com<\/a><\/p>\n<p>Erik Penser Bank \u00e4r bolagets Certified Adviser och n\u00e5s p\u00e5 08-463 83 00, e-post: certifiedadviser@penser.se<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-about\">\n<p><strong class=\"mfn-heading-1\">Om Nanexa AB (publ)<\/strong><\/p>\n<hr \/>\n<p>Nanexa AB \u00e4r ett nanoteknologiskt drug delivery-f\u00f6retag fokuserat p\u00e5 utvecklingen av PharmaShell\u00ae, ett nytt och banbrytande drug delivery-system med stor\u00a0potential inom ett flertal substanstyper och indikationsomr\u00e5den. Inom ramen f\u00f6r PharmaShell\u00ae utvecklar Nanexa egna produkter och har samarbetsavtal med flera l\u00e4kemedelsbolag, d\u00e4ribland\u00a0AstraZeneca.<\/p>\n<p>Nanexas aktie \u00e4r noterad p\u00e5 Nasdaq First North Growth Market i Stockholm (NANEXA).<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-attachment mfn-attachment-general\">\n<p><strong class=\"mfn-heading-1\">Bifogade filer<\/strong><\/p>\n<hr \/>\n<p><a class=\"mfn-generated mfn-primary\" href=\"https:\/\/storage.mfn.se\/033d51f2-52e5-4702-9655-1766ac40a190\/nanexa-tecknar-ytterligare-utvarderingsavtal.pdf\" target=\"_blank\" rel=\"nofollow noopener\">Nanexa tecknar ytterligare utv\u00e4rderingsavtal<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Nanexa AB meddelar idag att bolaget har tecknat ytterligare ett s\u00e5 kallat Material Transfer and Feasibility Study Agreement med en av bolagets befintliga kunder, f\u00f6r utv\u00e4rdering av PharmaShell\u00ae-teknologin med en specifik biologisk l\u00e4kemedelssubstans.<\/p>\n","protected":false},"template":"","class_list":["post-4728","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-ci_sv","mfn-news-tag-mfn-type-ir_sv","mfn-news-tag-mfn_sv","mfn-news-tag-mfn-ci-other_sv","mfn-news-tag-mfn-lang-sv_sv"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nanexa tecknar ytterligare utv\u00e4rderingsavtal - Nanexa AB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanexa.com\/mfn_news\/nanexa-tecknar-ytterligare-utvarderingsavtal\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanexa tecknar ytterligare utv\u00e4rderingsavtal - Nanexa AB\" \/>\n<meta property=\"og:description\" content=\"Nanexa AB meddelar idag att bolaget har tecknat ytterligare ett s\u00e5 kallat Material Transfer and Feasibility Study Agreement med en av bolagets befintliga kunder, f\u00f6r utv\u00e4rdering av PharmaShell\u00ae-teknologin med en specifik biologisk l\u00e4kemedelssubstans.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanexa.com\/mfn_news\/nanexa-tecknar-ytterligare-utvarderingsavtal\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanexa AB\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minut\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-tecknar-ytterligare-utvarderingsavtal\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-tecknar-ytterligare-utvarderingsavtal\\\/\",\"name\":\"Nanexa tecknar ytterligare utv\u00e4rderingsavtal - Nanexa AB\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\"},\"datePublished\":\"2021-10-13T10:40:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-tecknar-ytterligare-utvarderingsavtal\\\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-tecknar-ytterligare-utvarderingsavtal\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-tecknar-ytterligare-utvarderingsavtal\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Hem\",\"item\":\"https:\\\/\\\/nanexa.com\\\/sv\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN News Items\",\"item\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Nanexa tecknar ytterligare utv\u00e4rderingsavtal\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"name\":\"Nanexa AB\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanexa.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\",\"name\":\"Nanexa AB\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sv-SE\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"contentUrl\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"width\":165,\"height\":50,\"caption\":\"Nanexa AB\"},\"image\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanexa tecknar ytterligare utv\u00e4rderingsavtal - Nanexa AB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanexa.com\/mfn_news\/nanexa-tecknar-ytterligare-utvarderingsavtal\/","og_locale":"sv_SE","og_type":"article","og_title":"Nanexa tecknar ytterligare utv\u00e4rderingsavtal - Nanexa AB","og_description":"Nanexa AB meddelar idag att bolaget har tecknat ytterligare ett s\u00e5 kallat Material Transfer and Feasibility Study Agreement med en av bolagets befintliga kunder, f\u00f6r utv\u00e4rdering av PharmaShell\u00ae-teknologin med en specifik biologisk l\u00e4kemedelssubstans.","og_url":"https:\/\/nanexa.com\/mfn_news\/nanexa-tecknar-ytterligare-utvarderingsavtal\/","og_site_name":"Nanexa AB","twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"1 minut"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-tecknar-ytterligare-utvarderingsavtal\/","url":"https:\/\/nanexa.com\/mfn_news\/nanexa-tecknar-ytterligare-utvarderingsavtal\/","name":"Nanexa tecknar ytterligare utv\u00e4rderingsavtal - Nanexa AB","isPartOf":{"@id":"https:\/\/nanexa.com\/#website"},"datePublished":"2021-10-13T10:40:00+00:00","breadcrumb":{"@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-tecknar-ytterligare-utvarderingsavtal\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanexa.com\/mfn_news\/nanexa-tecknar-ytterligare-utvarderingsavtal\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-tecknar-ytterligare-utvarderingsavtal\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Hem","item":"https:\/\/nanexa.com\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN News Items","item":"https:\/\/nanexa.com\/mfn_news\/"},{"@type":"ListItem","position":3,"name":"Nanexa tecknar ytterligare utv\u00e4rderingsavtal"}]},{"@type":"WebSite","@id":"https:\/\/nanexa.com\/#website","url":"https:\/\/nanexa.com\/","name":"Nanexa AB","description":"","publisher":{"@id":"https:\/\/nanexa.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanexa.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"},{"@type":"Organization","@id":"https:\/\/nanexa.com\/#organization","name":"Nanexa AB","url":"https:\/\/nanexa.com\/","logo":{"@type":"ImageObject","inLanguage":"sv-SE","@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","contentUrl":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","width":165,"height":50,"caption":"Nanexa AB"},"image":{"@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news\/4728","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/media?parent=4728"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}